NIH Analysis Reveals a Significant Rise in Use of Complementary Health Approaches, Especially for Pain Management
January 31, 2024 -- An analysis conducted by the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH) reveals a substantial increase in the overall use of complementary health approaches by... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 31, 2024 Category: Pharmaceuticals Source Type: clinical trials
Switching to Vegan or Ketogenic Diet Rapidly Impacts Immune System
NIH study finds distinct immune responses occur quickly when diets change, more research needed to determine health effects.
January 30, 2024 -- Researchers at the National Institutes of Health observed rapid and distinct immune system changes... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 30, 2024 Category: Pharmaceuticals Source Type: clinical trials
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
BOSTON--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 30, 2024 Category: Pharmaceuticals Source Type: clinical trials
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
DUBLIN and CHICAGO, Jan. 30, 2024 /PRNewswire/ -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 30, 2024 Category: Pharmaceuticals Source Type: clinical trials
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech ’s NT-I7 for Advanced Pancreatic Cancer Treatment
January 30, 2024— ROCKVILLE, MD --- Pancreatic cancer has the highest mortality rate of all major cancers with only a 3% relative-survival-rate at 5-years for the advanced form.[i], [ii]- Pancreatic tumors are highly resistant to chemotherapy... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 30, 2024 Category: Pharmaceuticals Source Type: clinical trials
FDA Revises Letter of Authorization for the Emergency Use Authorization for Paxlovid
January 29, 2024 -- In December 2021, FDA authorized Paxlovid for emergency use for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 29, 2024 Category: Pharmaceuticals Source Type: clinical trials
First Patient Enrolled in Rise Therapeutics' Rheumatoid Arthritis Clinical Trial
ROCKVILLE, Md., Jan. 29, 2024. Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 29, 2024 Category: Pharmaceuticals Source Type: clinical trials
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
MINNEAPOLIS, Minn., January 28, 2024 – Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced new data presented today at the 60th Annual Meeting of The Society of Thoracic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 28, 2024 Category: Pharmaceuticals Source Type: clinical trials
Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
HELSINKI, Jan. 26, 2024. Nanoform Finland Plc ( " Nanoform " ), the medicine performance-enhancing company, today announced that one of its leading nanoformulation drug products had received promising clinical results. These were from a relative... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 26, 2024 Category: Pharmaceuticals Source Type: clinical trials
FDA Agrees to Amend Special Protocol Assessment for Clinical Trial of AXPAXLI in Wet AMD
BEDFORD, Mass., Jan. 25, 2024 . Ocular Therapeutix, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment
Placebo cohort participants who crossed over to atacicept 150 mg in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 25, 2024 Category: Pharmaceuticals Source Type: clinical trials
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ( " Ensysce " or the " Company " ) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced receipt of notice... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 23, 2024 Category: Pharmaceuticals Source Type: clinical trials
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss
AK-OTOF is a gene... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 23, 2024 Category: Pharmaceuticals Source Type: clinical trials
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
EMERYVILLE, Calif., Jan. 19, 2024. Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it received... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01
IRVINE, Calif., Jan. 18, 2024. PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the cohort 1 first patient treated in its Phase 1 relapsed or... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
